Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2021-07-09 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 5, 2021, for Sonoma Pharmaceuticals, Inc. The key content is about a change in the company's independent registered public accounting firm, specifically engaging Frazier & Deeter, LLC for the fiscal year ending March 31, 2022, and the completion of the prior auditor's work. It includes disclosures about consultations and disagreements with the new auditor and a consent letter from the previous auditor. This type of filing is a regulatory announcement about changes in auditors and related disclosures, which fits the category of Regulatory Filings (RNS). The document length is 4364 characters, which is relatively short and consistent with a regulatory announcement rather than a full audit report or annual report. There is no detailed financial data or audit opinion included, so it is not an Audit Report (AR) or Annual Report (10-K). Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-07-09 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 1, 2021, by Sonoma Pharmaceuticals, Inc. The content focuses on employment agreements with key executives: the CEO, CFO, and COO. It details their salaries, bonuses, severance terms, and other employment conditions. The document does not contain financial statements or quarterly/yearly financial results. It is primarily an announcement of changes in senior management employment terms, which fits the category of Board/Management Information (MANG). The document is not a full annual or interim report, nor is it an earnings release or regulatory filing of another type. Therefore, the appropriate classification is MANG with high confidence.
2021-07-06 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the Form 10-K annual report for the period ended March 31, 2021, could not be filed on time due to the auditors requiring additional time to complete their audit. The document does not contain the actual 10-K report or financial data but is merely a notification about the delay in filing the 10-K. According to the 'MENU VS MEAL' rule, such a notification is classified as a Regulatory Filing (RNS) because it is an announcement related to a report, not the report itself.
2021-06-29 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2021, by Sonoma Pharmaceuticals, Inc. It reports the entry into a material definitive agreement (a licensing and distribution agreement) with EMC Pharma, LLC. The content focuses on the announcement of this agreement and includes an exhibit reference to the agreement itself. There are no financial statements or detailed financial data presented, nor is this a report of earnings, management discussion, or regulatory certification. The nature of the filing is an update on a material contract, which is typical for a Current Report on Form 8-K. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit into more specific categories like earnings release, management report, or capital update. The document length and content confirm it is not merely an announcement of a report but a standalone regulatory filing reporting a material event.
2021-03-31 English
CURRENT REPORT
Investor Presentation Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Sonoma Pharmaceuticals, Inc. It includes an Item 7.01 Regulation FD Disclosure stating that an updated investor presentation is attached as Exhibit 99.1. The text explicitly mentions that the attached document is an investor presentation for investor conferences in March 2021. There are no financial statements or detailed financial data included in this filing itself, only a reference to the presentation. The document length is 4668 characters, which is relatively short and consistent with an announcement or furnishing of a presentation rather than a full report. According to the classification rules, a document primarily furnishing an investor presentation should be classified as Investor Presentation (IP).
2021-03-04 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2020
2021-02-16 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.